Retail apocalypse victims. The future of clinical trials. Warren's words of wisdom.
The hot takes are coming
SoftBank is getting into early-stage investing with a reported $500M fund.
Of course, the “what does this mean for VC” hot takes have begun.
Several years ago, many of the larger VC funds all started seed funds and/or seed investing activities. Most of them soon deprioritized these efforts (quietly) when they realized what a PITA seed stage investing was.
Perhaps this time is different?
For clients who want to dig into where SoftBank is going, here are a couple of relevant research briefs:
In his 1996 letter to shareholders, Warren Buffett explains one of the cornerstones of his investing philosophy: avoid investing in anything revolutionary and go for the boring companies that are likely to be around for a long time.
We unpack this and 23 other important lessons from the last four decades of Berkshire Hathaway’s shareholder letters. Check them out here.
Closing up shop
It’s a tough time to be in retail. Retailers are facing struggling physical storefronts, massive debt, and inefficient operations, among other issues.
Last month, Payless filed for its second bankruptcy in two years. Denim fashion brand Diesel USA filed for bankruptcy just last week. And they’re not alone.
The $65B clinical trial market needs an upgrade. Trials are costly and time-intensive for patients and stakeholders. Many fail due to enrollment issues.
AI could change all of that. From matching patients and trials to enrollment to data collection, we examine how the technology could streamline every stage of the clinical trial process. Check it out here.
Do it for the children
The coastal elites are it again.
This time, New York City parents are dropping up to $100K on Instagram-friendly luxury nurseries.